Sfoglia per Autore  ELLI, ELENA MARIA

Opzioni
Mostrati risultati da 1 a 20 di 21
Titolo Tipologia Data di pubblicazione Autori File
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 01 - Articolo su rivista 2024 Crespiatico I.Mastini C.D'Aliberti D.Mauri M.Mercado C. M.Fontana D.Spinelli S.Crippa V.Inzoli E.Manghisi B.Civettini I.Ramazzotti D.Sangiorgio V.Brambilla V.Aroldi A.Barone C.Orsenigo R.Serafini M.Mottadelli F.Cazzaniga G.Pagni F.Azzoni E.Gambacorti Passerini C.Elli E. M.Mologni L.Piazza R. +
Idiopathic erythrocytosis: a germline disease? 01 - Articolo su rivista 2024 Elli, E. M.Mauri, M.D’Aliberti, D.Crespiatico, I.Fontana, D.Redaelli, S.Pelucchi, S.Spinelli, S.Manghisi, B.Cavalca, F.Aroldi, A.Ripamonti, A.Palamini, S.Mottadelli, F.Massimino, L.Ramazzotti, D.Cazzaniga, G.Piperno, A.Gambacorti-Passerini, C.Piazza, R. +
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review 01 - Articolo su rivista 2023 Diletta FontanaElena M. ElliFabio PagniRocco Piazza
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia 01 - Articolo su rivista 2023 Inzoli E.Civettini I.Montelisciani L.Antolini L.Gambacorti-Passerini C.Elli E. M. +
Large-Scale Analysis of SARS-CoV-2 Synonymous Mutations Reveals the Adaptation to the Human Codon Usage During the Virus Evolution 01 - Articolo su rivista 2022 Ramazzotti, DanieleAngaroni, FabrizioMaspero, DavideMauri, MarioD’Aliberti, DeborahFontana, DilettaAntoniotti, MarcoElli, Elena MariaGraudenzi, AlexPiazza, Rocco
Clinical and Molecular features of the patients with Idiopathic Erythrocytosis 02 - Intervento a convegno 2022 Elli, EMauri, MD’Aliberti, DCrespiatico, IFontana, DRedaelli, SPelucchi, SManghisi, BCavalca, FRipamonti, ARamazzotti, DPiperno, AGambacorti Passerini, CPiazza, R +
Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis 01 - Articolo su rivista 2021 Rambaldi B.Donsante S.Di Marzo N.Dander E.Pioltelli P.Biondi A.Elli E. M.Pievani A.Serafini M. +
Being a Myeloproliferative Patient in COVID-19 Era: The Mytico Study 01 - Articolo su rivista 2021 Cavalca, FZambrotta, GPMGambacorti Passerini, CElli, EM +
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 01 - Articolo su rivista 2020 Fontana, DilettaRamazzotti, DanieleAroldi, AndreaRedaelli, SaraMagistroni, VeraPirola, AlessandraMassimino, LucaMastini, CristinaBombelli, SilviaElli, Elena MariaFumagalli, MonicaPerego, Roberto APagni, FabioMologni, LucaPiazza, RoccoGambacorti-Passerini, Carlo +
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study 01 - Articolo su rivista 2020 Elli, Elena MariaAntolini, LauraPasserini, Carlo Gambacorti- +
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors 01 - Articolo su rivista 2019 Elli E.Aroldi A. +
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 02 - Intervento a convegno 2019 Diletta FontanaDaniele RamazzottiAndrea AroldiLuca MassiminoElena Maria ElliMonica FumagalliRocco PiazzaCarlo Gambacorti-Passerini +
Paired Exome Sequencing Reveals Recurrent Germline Variants in Patients with Idiopathic Erythrocytosis 02 - Intervento a convegno 2019 Mauri, MElli, ED'Aliberti, DCrespiatico, INava, MMassimino, LFontana, DRedaelli, SBombelli, SPelucchi, SPerego, RPiperno, AGambacorti Passerini, CPiazza, R +
JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib 01 - Articolo su rivista 2018 Elli E. M.L'Imperio V.Berti E. +
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy 01 - Articolo su rivista 2016 Aroldi A.Pioltelli P. E.Pogliani E. M.Elli E. M. +
Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission 01 - Articolo su rivista 2015 Fumagalli, MonicaCOLNAGHI, FEDERICAElli, ElenaBelotti, AngeloCazzaniga, GiovanniPogliani, Enrico MariaPioltelli, Pietro +
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis 01 - Articolo su rivista 2014 Elli E. M.Aroldi A.Pioltelli P.Pogliani E. M. +
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 02 - Intervento a convegno 2014 DONADONI, CARLAPIAZZA, ROCCO GIOVANNIFONTANA, DILETTAPIROLA, ALESSANDRAREDAELLI, SARASPINELLI, ROBERTAMAGISTRONI, VERAGAIPA, GIUSEPPEPERONACI, MARCOELLI, ELENA MARIAGAMBACORTI PASSERINI, CARLO +
A CASE OF ATYPICAL PROLONGED HEMATOLOGIC TOXICITY WITH AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML), REVIEW OF LITERATURE AND A PROPOSAL OF MANAGEMENT 01 - Articolo su rivista 2012 ELLI, ELENA MARIABELOTTI, ANGELOPOGLIANI, ENRICO MARIA +
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 01 - Articolo su rivista 2012 FINAZZI, MARIA CHIARAELLI, ELENA MARIAPOGLIANI, ENRICO MARIA +
Mostrati risultati da 1 a 20 di 21
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile